389 related articles for article (PubMed ID: 22784018)
1. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.
Sani G; Serra G; Kotzalidis GD; Romano S; Tamorri SM; Manfredi G; Caloro M; Telesforo CL; Caltagirone SS; Panaccione I; Simonetti A; Demontis F; Serra G; Girardi P
CNS Drugs; 2012 Aug; 26(8):663-90. PubMed ID: 22784018
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
3. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
Molinuevo JL; Lladó A; Rami L
Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
[TBL] [Abstract][Full Text] [Related]
4. Memantine: an antiglutamatergic option for dementia.
Molinuevo JL; Garcia-Gil V; Villar A
Am J Alzheimers Dis Other Demen; 2004; 19(1):10-8. PubMed ID: 15002339
[TBL] [Abstract][Full Text] [Related]
5. Clinical Indications of Memantine in Psychiatry-Science or Art?
Aljuwaiser M; Alayadhi N; Ozidu V; Shafik Zakhari SA; Rushdy R; Naguy A
Psychopharmacol Bull; 2023 Feb; 53(1):30-38. PubMed ID: 36873917
[TBL] [Abstract][Full Text] [Related]
6. Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia.
Molina JL; Voytek B; Thomas ML; Joshi YB; Bhakta SG; Talledo JA; Swerdlow NR; Light GA
Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Jun; 5(6):562-568. PubMed ID: 32340927
[TBL] [Abstract][Full Text] [Related]
7. The Potential Effects of the Ketogenic Diet in the Prevention and Co-Treatment of Stress, Anxiety, Depression, Schizophrenia, and Bipolar Disorder: From the Basic Research to the Clinical Practice.
Chrysafi M; Jacovides C; Papadopoulou SK; Psara E; Vorvolakos T; Antonopoulou M; Dakanalis A; Martin M; Voulgaridou G; Pritsa A; Mentzelou M; Giaginis C
Nutrients; 2024 May; 16(11):. PubMed ID: 38892480
[TBL] [Abstract][Full Text] [Related]
8. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.
Sharma A; Gerbarg P; Bottiglieri T; Massoumi L; Carpenter LL; Lavretsky H; Muskin PR; Brown RP; Mischoulon D;
J Clin Psychiatry; 2017 Jun; 78(6):e656-e667. PubMed ID: 28682528
[TBL] [Abstract][Full Text] [Related]
9. Memantine for the Treatment of Behavioral Disturbance in Unspecified Major Neurocognitive Disorder.
Terry PH; Seoudy K; Lee MS; Stevenson KA
Cureus; 2021 Sep; 13(9):e17685. PubMed ID: 34650860
[TBL] [Abstract][Full Text] [Related]
10. Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types.
Fessel J
Discov Ment Health; 2023 Jan; 3(1):3. PubMed ID: 37861813
[TBL] [Abstract][Full Text] [Related]
11. Potential mechanisms of action of resveratrol in prevention and therapy for mental disorders.
Menegas S; Keller GS; Possamai-Della T; Aguiar-Geraldo JM; Quevedo J; Valvassori SS
J Nutr Biochem; 2023 Nov; 121():109435. PubMed ID: 37669710
[TBL] [Abstract][Full Text] [Related]
12. Memantine: a review of possible uses in child and adolescent psychiatry.
Hosenbocus S; Chahal R
J Can Acad Child Adolesc Psychiatry; 2013 May; 22(2):166-71. PubMed ID: 23667364
[TBL] [Abstract][Full Text] [Related]
13. Memantine: New prospective in bipolar disorder treatment.
Serra G; Demontis F; Serra F; De Chiara L; Spoto A; Girardi P; Vidotto G; Serra G
World J Psychiatry; 2014 Dec; 4(4):80-90. PubMed ID: 25540723
[TBL] [Abstract][Full Text] [Related]
14. Memantine in the Treatment of Executive Function Deficits in Adults With ADHD.
Biederman J; Fried R; Tarko L; Surman C; Spencer T; Pope A; Grossman R; McDermott K; Woodworth KY; Faraone SV
J Atten Disord; 2017 Feb; 21(4):343-352. PubMed ID: 24970718
[TBL] [Abstract][Full Text] [Related]
15. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder.
Serra G; Koukopoulos A; De Chiara L; Koukopoulos AE; Tondo L; Girardi P; Baldessarini RJ; Serra G
J Clin Psychiatry; 2015 Jan; 76(1):e91-7. PubMed ID: 25650685
[TBL] [Abstract][Full Text] [Related]
16. Memantine as an augmentation therapy for anxiety disorders.
Schwartz TL; Siddiqui UA; Raza S
Case Rep Psychiatry; 2012; 2012():749796. PubMed ID: 22937414
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
Smith EG; Deligiannidis KM; Ulbricht CM; Landolin CS; Patel JK; Rothschild AJ
J Clin Psychiatry; 2013 Oct; 74(10):966-73. PubMed ID: 24229746
[TBL] [Abstract][Full Text] [Related]
18. The use of memantine in neuropsychiatric disorders: An overview.
Lu S; Nasrallah HA
Ann Clin Psychiatry; 2018 Aug; 30(3):234-248. PubMed ID: 30028898
[TBL] [Abstract][Full Text] [Related]
19. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.
Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang YS; Wang LJ; Lee IH; Wang TY; Yeh TL; Yang YK; Hong JS; Lu RB
J Clin Psychopharmacol; 2014 Jun; 34(3):337-43. PubMed ID: 24717258
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
